| [1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| [2] |
李星, 曾晓勇. 中国前列腺癌流行病学研究进展[J]. 肿瘤防治研究, 2021, 48(01): 98-102.
|
| [3] |
中国抗癌协会泌尿男生殖系统肿瘤专业委员会. 前列腺癌骨转移临床诊疗专家共识（2021版）[J]. 中华肿瘤杂志, 2021, 43(10): 1007-1015.
|
| [4] |
Huang JF, Shen J, Li X, et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study[J]. Ann Transl Med, 2020, 8(7): 482.
|
| [5] |
Bhowmik D, Song X, Intorcia M, et al. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population[J]. Curr Med Res Opin, 2019, 35(3): 513-523.
|
| [6] |
Kokorovic A, So AI, Serag H, et al. Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies[J]. Can Urol Assoc J, 2021, 15(6): E307-E322.
|
| [7] |
Feng W, Guo J, Li M. RANKL-independent modulation of osteoclastogenesis[J]. J Oral Biosci, 2019, 61(1): 16-21.
|
| [8] |
Chen X, Wang Z, Duan N, et al. Osteoblast-osteoclast interactions[J]. Connect Tissue Res, 2018, 59(2): 99-107.
|
| [9] |
D'Andrea S, Martorella A, Coccia F, et al. Relationship of Vitamin D status with testosterone levels: a systematic review and meta-analysis[J]. Endocrine, 2021, 72(1): 49-61.
|
| [10] |
Giustina A, Adler RA, Binkley N, et al. Consensus statement from 2(nd) International Conference on Controversies in Vitamin D[J]. Rev Endocr Metab Disord, 2020, 21(1): 89-116.
|
| [11] |
Nair-Shalliker V, Bang A, Egger S, et al. Post-treatment levels of plasma 25- and 1,25-dihydroxy vitamin D and mortality in men with aggressive prostate cancer[J]. Sci Rep, 2020, 10(1): 736.
|
| [12] |
Bouillon R, Marcocci C, Carmeliet G, et al. Skeletal and extraskeletal actions of vitamin d: current evidence and outstanding questions[J]. Endocr Rev, 2019, 40(4): 1109-1151.
|
| [13] |
Kim DK, Lee JY, Kim KJ, et al. Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis[J]. J Clin Med, 2019, 8(1).
|
| [14] |
Hirbe A, Morgan EA, Uluckan O, et al. Skeletal complications of breast cancer therapies[J]. Clin Cancer Res, 2006, 12(20 Pt 2): 6309s-6314s.
|
| [15] |
Wallander M, Axelsson KF, Lundh D, et al. Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO)[J]. Osteoporos Int, 2019, 30(1): 115-125.
|
| [16] |
Morgia G, Russo GI, Tubaro A, et al. Prevalence of cardiovascular disease and osteoporosis during androgen deprivation therapy prescription discordant to EAU Guidelines: results from a multicenter, cross-sectional analysis from the CHOsIng treatment for prostate canCEr (CHOICE) study[J]. Urology, 2016, 96: 165-170.
|
| [17] |
黄展森, 狄金明. 2022版欧洲泌尿外科学会前列腺癌诊疗指南更新要点解读[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(6): 483-488.
|
| [18] |
Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment[J]. Nat Rev Endocrinol, 2020, 16(8): 437-447.
|
| [19] |
Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group[J]. Osteoporos Int, 1994, 4(6): 368-381.
|
| [20] |
夏维波,章振林, 林华, 等.原发性骨质疏松症诊疗指南(2017)[J]. 中国骨质疏松杂志, 2019, 25(03): 281-309.
|
| [21] |
中华医学会骨质疏松和骨矿盐疾病分会. 男性骨质疏松症诊疗指南[J]. 中华骨质疏松和骨矿盐疾病杂志, 2020, 13(05): 381-395.
|
| [22] |
Gillessen S, Attard G, Beer TM, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017[J]. Eur Urol, 2018, 73(2): 178-211.
|
| [23] |
Gillessen S, Attard G, Beer TM, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[J]. Eur Urol, 2020, 77(4): 508-547.
|
| [24] |
Vescini F, Attanasio R, Balestrieri A, et al. Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis[J]. J Endocrinol Invest, 2016, 39(7): 807-834.
|
| [25] |
Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent[J]. Eur Urol, 2021, 79(2): 243-262.
|
| [26] |
Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021[J]. J Natl Compr Canc Netw, 2021, 19(2): 134-143.
|
| [27] |
Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(9): 1119-1134.
|
| [28] |
Newton RU, Galvao DA, Spry N, et al. Exercise Mode Specificity for Preserving Spine and Hip Bone Mineral Density in Prostate Cancer Patients[J]. Med Sci Sports Exerc, 2019, 51(4): 607-614.
|
| [29] |
Taaffe DR, Galvao DA, Spry N, et al. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition[J]. BJU Int, 2019, 123(2): 261-269.
|
| [30] |
Handforth C, D'Oronzo S, Coleman R, et al. Cancer Treatment and Bone Health[J]. Calcif Tissue Int, 2018, 102(2): 251-264.
|
| [31] |
Boanini E, Torricelli P, Gazzano M, et al. Combined effect of strontium and zoledronate on hydroxyapatite structure and bone cell responses[J]. Biomaterials, 2014, 35(21): 5619-5626.
|
| [32] |
Wang L, Fang D, Xu J, et al. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review[J]. BMC Cancer, 2020, 20(1): 1059.
|
| [33] |
Wu C, Chen W, Huang X, et al. Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer[J]. Clin Genitourin Cancer, 2018, 16(6): e1243-e1250.
|
| [34] |
Kojima I, Naito Y, Yamamoto A, et al. Efficacy of zoledronic acid in older prostate cancer patients undergoing androgen deprivation therapy[J]. Osteoporos Sarcopenia, 2019, 5(4): 128-131.
|
| [35] |
Poon Y, Pechlivanoglou P, Alibhai SMH, et al. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures[J]. BJU Int, 2018, 121(1): 17-28.
|
| [36] |
von Moos R, Costa L, Gonzalez-Suarez E, et al. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody[J]. Cancer Treat Rev, 2019, 76: 57-67.
|
| [37] |
Yoshida T, Kinoshita H, Taniguchi H, et al. A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study[J]. Osteoporos Int, 2020, 31(7): 1251-1259.
|
| [38] |
Hadji P, Aapro MS, Body JJ, et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG[J]. J Bone Oncol, 2017, 7: 1-12.
|
| [39] |
Jakob T, Tesfamariam YM, Macherey S, et al. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis[J]. Cochrane Database Syst Rev, 2020, 12(12): CD013020.
|